MGX
Metagenomi, Inc.
1.10$
-2.7%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 159.3% | 10.1% | 210.9% | 10.3% | 21.1% | |
| -59.3% | 89.9% | -110.9% | 100.0% | 78.9% | |
| 5,958.0% | 250.8% | 210.9% | 208.8% | 374.6% | |
| 3,996.7% | 108.7% | 64.4% | 61.2% | 106.3% | |
| 9,795.5% | 349.5% | 64.4% | 270.0% | 459.8% | |
| -9,854.7% | -259.5% | -175.4% | -170.0% | -380.9% | |
| 124.3% | 0.6% | 0.0% | – | – | |
| -8,823.9% | -238.5% | -134.6% | -159.8% | -348.8% | |
| 125.9% | 14.9% | 17.9% | -10.5% | -0.2% | |
| -8,823.9% | -253.4% | -152.5% | -149.3% | -348.5% | |
| -8,540.3% | -227.9% | -125.2% | -149.5% | -327.7% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.